PPT-OBV/PTV/r

OBVPTVr RBV Randomisation 1 1 Open label 1870 years Chronic HCV infection Genotype 4 Treatmentnaïve or failure t o PEGIFN RBV HCV RNA gt 10000 IUml No cirrhosis No HBV or HIV coinfection. s s eca e g a 2 e s y y d o g a 3 e 2 s li e a 3 ub e it hou t e r ce r ece s d n p e s ec mm d t ou ea d r t ea t l ook ov r e s il d o ee d ub e ea g s du e o e ac t t t t e hod nd it s e y e o ng e n a 2 ub e s s d e c ou r e ll s n e e no tt r N.M.M.Ramos(V.P.deFreitasLFCBuildingPhysicsLaboratory,CivilEngineeringDepartment,FacultyofEngineering,UniversityofPorto,4200-465Porto,Portugale-mail:nuno.ramos@fe.up.ptV.P.deFreitase-mail:vpfreita@fe. PTV150/r + OBV + . DSV . + RBV. PTV150/r + . DSV . + RBV. 2-steps. Randomisation*. Open-label. W12. W8. W24. 18-70 years. Chronic HCV infection . Genotype 1. HCV RNA ≥ 50,000 IU/ml. Treatment-naïve . Global Village Multicultural festival. Tram Information. From Flinders St Station . There are two ways to access the festival grounds if you are using a train to access the city: . Access from Swanson St would require a tram right on any of these trams routes: . Paritaprevir. -. Ritonavir (. Technivie. ). Prepared by: . David H. Spach, MD. Last . Updated: . July 27, 2015. Background and Dosing. Ombitasvir-Paritaprevir. -. Ritonavir (. Technivie. ) . Ombitasvir-Paritaprevir. *. 1:1. Open-label. ≥ 18 years. HCV genotype 4. HCV RNA ≥ 1 000 IU/mL. Naïve or pre-treated with PEG-IFN + RBV Compensated cirrhosis ** . No HBV or HIV co-infection. N = 59. W12. OPV/PTV/r + RBV. + DSV + RBV. No randomisation. Open-label. TOPAZ-II . Study. : OBV/PTV/r + DSV . +. RBV . for genotype 1. W24. >. 18 years. HCV infection, genotype 1. HCV RNA > 1,000 IU/ml. Naïve or pre-treated with . Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IFN + RBV. Randomisation. Open-label. 18-65 years. HCV genotype 1. HCV RNA > 10,000 IU/ml. Naïve (MALACHITE-I). Failure to . prior PEG-IFN + RBV. (MALACHITE-II). Feld JJ. NEJM . 2014;370:1594-1603. SAPPHIRE-I . Study. : . o. mbitasvir/paritaprevir/ritonavir. . + . d. asabuvir. . + . ribavirin. . for genotype 1. Treatment regimens. Co-formulated . ombitasvir. DSV . placebo. Randomisation*. Partial blind. 18-70 years. Chronic HCV infection. Genotype 1 . Treatment-naïve. HCV RNA > 10,000 IU/ml. No cirrhosis. No HBV or HIV co-infection. * Randomisation 1:2 if genotype 1a (PEARL-IV) ; . ≥ 18 years. Chronic HCV infection. Genotype 1. Treatment-. naïve or . PEG-IFN RBV-. experienced . HCV RNA > 1,000 IU/ml. Chronic kidney disease with. eGFR. (MDRD) < 30 ml/min/1.73m. 2. (dialysis permitted). IAPAC African Regional Capacity-Building Hub. Based in Johannesburg, South Africa. Mission: Strengthen clinician capacity to deliver HIV, HBV, and HCV treatment . Partners include:. . Supported through an educational grant from: . IAPAC African Regional Capacity-Building Hub. Based in Johannesburg, South Africa. Mission: Strengthen clinician capacity to deliver HIV, HBV, and HCV treatment . Partners include:. . Supported through an educational grant from: . electrons for mixed beam radiotherapy. Theodoros Christodoulou. Background. Cross tumor volume (GTV):. . primary tumor. Clinical target volume (CTV):. . subclinical microscopic disease that lies around the tumor mass.